Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine

Cancer Gene Therapy

Volumn 13, Issue 6, 2006, Pages 592-597

  Garcia Hernandez E ^a   Gonzalez Sanchez J L ^a   Andrade Manzano, A ^a   Contreras, M L ^b   Padilla, S ^c   Guzman C C ^a   Jimenez R ^d   Reyes, L ^d   Morosoli, G ^d   Verde, M L ^d   Rosales, R ^e,f  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Hospital de la Mujer   (Mexico)

^d SA de CV   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Carcinoma in situ; Clinical trial; MVA; Papillomavirus; Vaccinia virus

Indexed keywords

MVA E2 RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ADULT; ARTICLE; CANCER GRADING; CANCER REGRESSION; CARCINOMA IN SITU; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MEXICO; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION; UTERUS BIOPSY; VIRUS LOAD; VIRUS PARTICLE; WART VIRUS;

ADULT; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DEMOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT SELECTION; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VACCINIA VIRUS; VIRAL LOAD;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE; VACCINIA VIRUS;

EID: 33646817087     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700937     Document Type: Article

References (11)

1. Jansen K, Shaw A. Human papillomavirus vaccines and prevention of cervical cancer. Ann Rev Med 2004; 55: 319-331.
2. Parkin DM, Laara E, Muir CS. Estimates of the world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1980; 41: 184-197.
3. Rosales C, Valadez G, Arrellin R, Merchant H, Rosales R. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother 2000; 49: 347-360.
4. Valadez V, Sutter G, Jose M, Garcia-Carranca A, Erfle V, Moreno M et al. Human tumor growth is inhibited by vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 2000; 88: 1650.
5. Corona-Gutiérrez C, Tinoco A, Contreras M, Navarro T, Calzado P, Vargas L et al. A phase II study. Efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 2002; 13: 1127-1140.
6. Corona-Gutiérrez C, Tinoco A, Navarro T, López-Contreras M, Risco-Cortes R, Calzado P et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2 and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15: 421-431.
7. Binns MM, Smith GL. Recombinant Poxvirus. ACR Press: Boca Raton, Florida, 1993.
8. Sutter G, Wyatt LS, Foley PL, Bennick JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12: 53-59.
9. Roque-Reséndiz J, Rosales R, Herion P. MVA ROP 2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis. Parasitology 2004; 128: 397-405.
10. Hanke T, McMichael A, Mwau M, Wee EG, Ceberej I, Patel S et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002; 20: 1995-1998.
11. Wyatt L, Whitehead S, Venanzi K, Murphy B, Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999; 18: 392-397.